BREAKING: Redwire's SpaceMD has announced its first commercial mission aboard SpaceX's Starfall spacecraft. The mission aims to accelerate pharmaceutical development and microgravity manufacturing in space. • Launch planned for 2028. • SpaceMD will fly 32 PIL-BOXes—the largest dedicated commercial microgravity research mission ever flown. • The mission will support pharmaceutical, biotechnology, and other in-space manufacturing research. "Space-based pharmaceutical development is reaching an inflection point," said SpaceMD CEO John Vellinger, highlighting the combination of Redwire's flight-proven microgravity payloads with SpaceX's transportation capabilities to expand research capacity and accelerate the development of life-changing therapies.

"Processing pharmaceuticals in space, to benefit patients on earth." Delian Asparouhov, Co-Founder + President of @VardaSpace breaks down Varda's mission and its recently-announced research collaboration with United Therapeutics. The full conversation at @NYSE:

One of the biggest pharma companies in the world just got caught manipulating clinical trial data on a $3.7 billion drug. Patients are dying of liver failure. The FDA wants it pulled immediately. But Amgen is refusing. Here is what happened: In 2021 a tiny biotech called ChemoCentryx won FDA approval for Tavneos, a pill for a rare autoimmune disease called ANCA vasculitis. The FDA's own advisory committee had flagged concerns about the data. But approval went through anyway. A year later Amgen paid $3.7 billion to acquire ChemoCentryx for one reason: This single drug. CEO Robert Bradway called Tavneos "a terrific medicine, the first innovation in this space in more than 10 years." Then three years later the FDA discovered something through a securities fraud lawsuit filed against ChemoCentryx by its own shareholders: Court records showed that ChemoCentryx personnel handpicked 9 trial participants for "readjudication" after the original statistical analysis showed the drug did NOT actually work. 5 of those 9 had their clinical outcomes changed from "not in remission" to "sustained remission." The company then submitted the application for approval without ever disclosing the original analysis to the FDA. The FDA's own letter from April 27, 2026 quotes it directly: "Unblinded study personnel manipulated the results of the pivotal clinical study so the drug looked effective when the original analysis did not support that conclusion." The agency's conclusion was even more brutal: "CDER can no longer conclude that there is, or has ever been, a valid demonstration that Tavneos is effective." Then the post-market safety reports started rolling in. The FDA has documented multiple cases of serious drug-induced liver injury linked to Tavneos. Some have been fatal. Most of the deaths occurred in Japan, where the drug was also approved. In January 2026 the FDA asked Amgen to voluntarily withdraw the drug. But Amgen refused. And the reason is purely financial. Tavneos generated $459 million in revenue in 2025, up 62% year over year. Amgen NEEDS this growth desperately. Prolia and Xgeva lost patent protection last year. Repatha and Enbrel lose protection in 2028. Those four drugs combined represented $11.7 billion in annual sales. Tavneos is supposed to plug the hole. So instead of pulling it, Amgen has hired its own consultants to "independently" reanalyze the exact data the FDA has already concluded was manipulated. The company has formally requested a public hearing to defend the drug. The hearing has not been scheduled. Roughly 8,000 patients are currently being prescribed Tavneos worldwide. This is the third largest biotech in America defying the FDA's direct request to pull a drug the agency has formally concluded was approved based on fraud and is now associated with patient deaths. Amgen approved a $3.7 billion acquisition of a single-drug company on the basis of clinical data the FDA has now concluded was manipulated before the acquisition even closed. Either Amgen knew about the data problems and bought the company anyway, or the most expensive due diligence process in pharmaceutical history failed at the highest level. Both options are scary. Why is a drug that the FDA has formally concluded was never proven effective, and that is linked to fatal liver injuries, still being prescribed to thousands of patients in the United States today? The FDA has the legal authority to forcibly withdraw approval after a public hearing but it has not used that authority yet. Amgen is gambling that the political weight of the pharmaceutical lobby will outlast the regulatory will of an FDA Commissioner who built his reputation on cracking down on the industry. The drug is still on shelves. Prescriptions are still being written. How does this end?

━━━━━━━━━━━━━ 【US Listed Stocks Implied Catalyst Brief】🔍 ━━━━━━━━━━━━━ 📅 Date: July 22, 2026 (Wednesday) 🌍 Market: US Equities (NYSE + NASDAQ) 【Executive Summary】 Late July brings a dense calendar of macro data and earnings season for US stocks. Three under-the-radar trends to watch this week: ① Small-cap SaaS firms witness coordinated buying by CEOs and directors ($EVCM, Palisade Bio); insiders start accumulating shares after steep valuation compression. ② Bridgewater’s Q2 13F filings reveal a sharp 70% cut to Apple alongside a 62% increase in $AMD holdings, a clear signal of rotation within AI hardware names. ③ Biotech PDUFA season kicks off; $OTLK faces a July 29 FDA decision with an estimated 89% approval probability. I. Major SEC Filing Announcements (Past 1–2 Weeks) ■ $EVCM EverCommerce Inc. (8-K + Form 4, July 8) CEO Eric Remer purchased 75,000 shares at $9.98 ($748,500). Director Richard Peretz bought 100,000 shares ($995,000). Director Eric Rosenthal acquired 60,000 shares ($601,200). The three executives collectively purchased 235,000 shares on the same day for a total of $2.34 million, marking the largest single-day insider purchase in 18 months. The firm recently divested non-core businesses; its stock trades near the 52-week low of $9.45 with a PS ratio of only 1.8x, representing a 40% discount versus the peer median of 3.0x. ■ $BABA Alibaba Group (8-K, Ongoing Share Repurchases) Repurchases executed between July 2–8: 4.16 million shares on July 2 ($49.99 million); 1.47 million shares on July 8 ($19.99 million). Cumulative repurchases since program authorization stand at 31.26 million shares (0.16% of total shares outstanding). Current trailing PE stands at roughly 12x, within its historical low range. ■ $KR Kroger Co. (8-K, July 1) Definitive agreement to acquire Giant Eagle for a total consideration of $1.65 billion ($1.25 billion cash plus assumption of $400 million debt). Giant Eagle generates approximately $9 billion in annual revenue and operates 197 supermarkets plus 11 pharmacies, with geographic footprints highly complementary to Kroger’s existing markets (OH/PA/WV/MD/IN). II. Insider Trading Activity (Form 4, Past 1–2 Weeks) ■ $EVCM EverCommerce — ⭐Strong Signal CEO and two directors made coordinated purchases totaling $2.34 million on July 8 at average prices ranging $9.75–$10.15. Short interest remains elevated at 8.5% of the float, creating potential short squeeze dynamics on upward price moves. A comparable cluster insider purchase worth $1.8 million in December 2024 preceded a 22% share price gain within six weeks. ■ $FLD Fold Holdings — ⭐CEO Accumulation CEO purchased 250,000 shares at $2.60 on July 6 ($650,000), lifting direct holdings by roughly 15%. The stock sits merely 8% above its 52-week low of $2.40. Q2 earnings are scheduled for July 25. Open interest on $3.00 strike call options has risen noticeably in recent sessions. ■ $PALI Palisade Bio — ⭐Serial Director Buying Director Robert Baltera Jr. completed three tranches of purchases between July 1–8 totaling 125,000 shares: $1.98 (30,000), $2.04 (50,000), $1.97 (45,000), for approximately $250,000 total. His shareholding increased by 34%, representing the largest management purchase since January this year. ■ $ANET Arista Networks — ⚠️CEO Disposition CEO Jayshree Ullal sold approximately 477,000 shares across July 9–10 for aggregate proceeds of $89.5 million. While classified as routine selling, the sizable volume warrants monitoring. III. Institutional Position Shifts from 13F Filings (Latest Quarter) ■ Bridgewater Q2: Sharp 70% Cut to AAPL, +62% Stake Increase in AMD Total portfolio market value stood at $19.2 billion (a $600 million quarter-over-quarter decline). The most notable adjustment: substantial reduction in Apple (-70%), paired with a 420,000-share addition to AMD (+62%). Positions in TSM, NVDA, MU, AVGO, MRVL and other AI semiconductor names were retained. Bridgewater is rotating AI exposure away from richly valued large-cap leaders toward second-tier semiconductor stocks. ■ Berkshire Hathaway Q1 (First Post-Warren Buffett 13F) New $2.6 billion position in DAL (Delta Air Lines), marking a return to airline equities. Stake increase in GOOGL elevated it to the seventh-largest holding. New $55 million position in Macy’s. Full liquidation of AMZN and Visa. The new management team demonstrates a tilt toward value recovery and cyclical consumer plays. ■ Composite Signal: Q2 13F data reflects institutional “sell expensive, buy undervalued” positioning — trimming high-valued AI leaders including MSFT/NVDA/AAPL while adding AMD/MU/MRVL and other second-tier semiconductor names. Select institutions have begun tentative repositioning into rate-sensitive cyclicals such as airlines and retail. IV. Analyst Rating Revisions (Past 1–2 Weeks) ■ $XYZ Block — Piper Sandler Two-Tier Upgrade to Overweight Target price raised from $58 to $100 (+72%), driven by projected gross profit growth and margin expansion. Recent underperformance across payments and consumer finance stocks stems from valuation compression rather than EPS deterioration. The firm also assigned Overweight ratings to V/MA/AXP/AFRM/COF. ■ $FIVE Five Below — Bernstein Upgrade to Outperform Target price lifted from $247 to $250. Discount retailers stand to benefit from consumer downgrading trends amid weaker economic conditions. ■ $ADBE Adobe — HSBC upgraded to Buy ($308) on July 2, followed by another firm downgrade to Sell ($240) on July 21. Widening rating divergence reflects unresolved market debate over AI’s impact on creative software. Bulls argue Adobe Firefly unlocks new growth avenues; bears warn of market share erosion from competitors including Canva. ■ $PLTR Palantir — DA Davidson Upgrade to Buy Target price set at $175. Growth accelerates on both government and commercial demand for its AIP AI platform. ■ $SHOP Shopify — Stifel Upgrade to Buy Target price increased from $110 to $150. Consistent profitability improvement for the e-commerce SaaS platform. V. M&A & Corporate Combination Announcements (Past 1–2 Weeks) ■ GSK Acquisition of $NUVL Nuvalent — $10.6 Billion All-Cash Deal GSK closed its acquisition of Nuvalent on July 15 at $124 per share in all cash. Nuvalent develops precision oncology therapies targeting ALK/ROS1 mutations. The transaction featured a substantial acquisition premium, and Nuvalent delisted from Nasdaq. ■ $AA Alcoa Acquisition of South32 Aluminum Assets — Up to $5.6 Billion On July 1, Alcoa announced acquisition of South32’s integrated bauxite, alumina and aluminum smelting assets to solidify its position as the world’s largest aluminum producer. AA pre-market fell 3.6% on announcement amid investor concerns over overpayment, though scale advantages and cost synergies from integration merit follow-up. ■ $KR Kroger Acquisition of Giant Eagle — $1.65 Billion See Section I above. Kroger intends to accelerate Giant Eagle’s growth via data analytics, e-commerce solutions and operational discipline. VI. Share Repurchase Authorizations (Past 1–2 Weeks) ■ $NU Nu Holdings — New $1 Billion Buyback Program Board approved a 12-month $1 billion repurchase program on June 4. The Brazilian digital bank continues generating substantial excess capital while expanding into Mexico, Colombia and the United States. Current market capitalization stands at roughly $53 billion; the buyback represents approximately 1.9% of market value. ■ $NWSA News Corp — Ongoing $1 Billion Repurchase Program Aggregate repurchases reached $364 million as of July 14 (including a $2.72 million tranche on July 14). Approximately $636 million of authorization remains available, equivalent to 3–4% of market cap, signaling constructive capital return momentum. ■ $BABA Alibaba — Daily Buybacks Ranging $5–20 Million Repurchase pace accelerated in July. Cumulative repurchases since program launch total 31.26 million shares. Sustained buybacks at depressed price levels alongside a 12x PE ratio provide meaningful downside support. VII. FDA Biotech Catalysts ■ $OTLK Outlook Therapeutics (PDUFA July 29, 89% Probability) Bevacizumab BLA for wet age-related macular degeneration (Wet AMD). The regulatory decision is due in 9 days. If approved, it will serve as a lower-cost alternative to Lucentis, with an addressable annual market exceeding $8 billion. Current market cap sits near $300 million; regulatory results will dictate near-term price trajectory. ■ $CAPR Capricor Therapeutics (PDUFA August 22, 67% Probability) Deramiocel for Duchenne Muscular Dystrophy (DMD) cardiomyopathy. The candidate holds Orphan Drug, Rare Pediatric Disease and Fast Track designations amid urgent unmet patient needs. The 67% approval probability implies elevated uncertainty, yet substantial upside potential upon clearance. ■ $CELC Celcuity (PDUFA Date Elapsed, July 20) Gedatolisib for second-line HR+/HER2- breast cancer, granted Priority Review, Breakthrough Therapy and Fast Track status with a historical approval probability of ~90%. The PDUFA deadline passed July 20; official regulatory conclusions await confirmation. ■ $SMMT Summit Therapeutics (PDUFA November 14) BLA submission for EGFR-mutant NSCLC post-TKI treatment failure. Approval would fill an unmet clinical niche for EGFR resistance cases. VIII. Retail Social Media Trending Equities (Past 1–2 Weeks) ■ $SNAP Snap Inc. — Reddit Discussion Volume +633% Spiking social sentiment likely tied to Q2 earnings expectations due late July. Fundamentals remain pressured by fierce advertising competition, while the potential TikTok ban remains unresolved. ■ $SPCX SpaceX — Sustained Retail Investor Enthusiasm 677 Reddit mentions with 78.6% bullish sentiment. SpaceX remains the primary accessible space-sector name for retail investors, keeping sentiment elevated. Valuation bubble risks require vigilance. ■ $GME GameStop — Meme Stock Revival 586 Reddit mentions with 152.6% bullish tilt. July rebound correlates with upcoming Q2 earnings and potential transformation catalysts, though no fundamental inflection is confirmed; price action is largely sentiment-driven. ■ $MU Micron Technology — Heated Bull-Bear Debate 714 Reddit mentions with largely neutral sentiment (only 2.3% bullish). Headwinds include Korean semiconductor financing risks, balanced against long-term HBM demand; market direction remains highly contested. ━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 【Ranked Watchlist】Top 5 High-Potential Equities ━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 🥇 #1#: $EVCM EverCommerce Inc. Core Catalysts: Coordinated insider purchases totaling $2.34 million by CEO and two directors on July 8, the largest cluster management acquisition in 18 months. PS ratio of 1.8x versus peer median 3.0x; non-core asset divestitures set the stage for operating margin improvement. Key Metrics: Share price ~$10.5, market cap $1.85 billion, short interest 8.5% (short squeeze potential). Risks: Small-business SaaS spending may contract amid elevated interest rates; stock remains within a downtrend. Positioning Note: Suitable for medium-to-long-term accumulation on dips. Entry zone $9.5–$10, stop-loss $8.5 (10% below 52-week trough). Target range $13–$15 (implying reversion to 2.5x PS). ━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 🥈 #2#: $XYZ Block Inc. Core Catalysts: Piper Sandler two-tier upgrade to Overweight; target lifted from $58 to $100 (+72%). Gross profit expansion driven by Square merchant ecosystem and Cash App dual engines. Valuations across the payments sector have undergone significant compression. Key Metrics: Current share price ~$75, target $100, PE has retreated to reasonable territory. Risks: Rising consumer loan credit losses, volatile bitcoin-derived revenue, ongoing regulatory uncertainty. Positioning Note: Enter $70–$75 zone, stop-loss $62. Upside toward $95–$100 if Q2 earnings (early August) validate margin expansion. ━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 🥉 #3#: $AMD Advanced Micro Devices Core Catalysts: Bridgewater lifted AMD holdings by 62% in Q2. Institutional capital is rotating out of NVDA toward second-tier AI semiconductor names. MI300/MI400 ramp accelerates, building AMD’s nascent data center GPU footprint. Key Metrics: Clear Q2 institutional accumulation signal; AMD holds cost-performance advantages over NVDA within AI inference workloads. Risks: Competitive pressure from NVIDIA Blackwell architecture, sentiment spillover from Korean semiconductor financing strains, persistent weakness in PC end-markets. Positioning Note: Existing holders may maintain positions; new entries await the $160–$165 zone. Accelerated adoption in AI inference represents the primary H2 2026 catalyst. Stop-loss $140. ━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 🏅 #4#: $OTLK Outlook Therapeutics Core Catalysts: July 29 PDUFA decision (9 days away) for Bevacizumab in Wet AMD with an 89% historical approval probability. Approval would create a low-cost alternative to Lucentis within an $8 billion+ annual addressable market. Key Metrics: Current market cap ~$300 million, PDUFA scheduled July 29. Risks: Severe share price downside if FDA issues a Complete Response Letter (CRL); questions over manufacturing capacity and commercialization capabilities; potential need for partnerships or capital raises for launch. Positioning Note: High risk, high reward. Limit allocation to speculative tranches (≤2% of total portfolio). Pre-PDUFA share price rallies are typical. Reduce half of the position ahead of the decision date to lock in gains regardless of outcome. ━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 🏅 #5#: $BABA Alibaba Group Core Catalysts: Trailing PE of only 12x with sustained daily buybacks of $5–20 million. Top-tier institutions including Bridgewater and Appaloosa (David Tepper; BABA as the largest 11.7% portfolio holding) maintain heavy positions. Growth drivers include AI cloud and cross-border e-commerce. Key Metrics: Share price ~$120, PE 12x, daily buyback range $5–20 million. Risks: Uncertain domestic macro backdrop, US–China tech decoupling risks, intensifying competition from Pinduoduo and Douyin E-commerce. Positioning Note: Scale in tranches between $110–$120 for long-term holdings. The combination of 12x PE and active repurchases offers robust downside protection. Stop-loss $95. ━━━━━━━━━━━━━━━━━━━━━━━━━━━━ Follow, share and save. The Wall Street Watch team will continue tracking developments and interpreting quantitative data. Drawing on the WSV Model, we deliver analysis covering equities, gold, bonds (ETFs), sector rotation metrics and individual stock case studies to capture forward positioning opportunities. ⭐️⭐️⭐️ Disclaimer: All content is for informational reference only and shall not constitute investment advice or trading guidance. Information is compiled from public filings and calculated via quantitative machine learning models. No warranty is made regarding the authenticity, completeness or accuracy of data herein. Past performance does not guarantee future returns; case studies do not guarantee profitable outcomes. Investors act at their own risk. All investments carry risk.

WE HAVE NOW OFFICIALLY COMPLETED 7 OUT OF THE 12 MONTHS IN 2026 This is how every stock in the NASDAQ 100 has performed so far in 2026 Sandisk $SNDK +411.8%🟢 Western Digital $WDC +216.3%🟢 Seagate $STX +210.9%🟢 Micron $MU +188.4%🟢 Intel $INTC +144.4%🟢 Nebius $NBIS +127.5%🟢 AMD $AMD +122.3%🟢 Marvell $MRVL +120.7%🟢 Arm Holdings $ARM +119.3%🟢 Fortinet $FTNT +103.9%🟢 Applied Materials $AMAT +97.5%🟢 Datadog $DDOG +97.1%🟢 Lumentum $LITE +93.7%🟢 Teradyne $TER +90.0%🟢 Astera Labs $ALAB +87.1%🟢 Palo Alto $PANW +80.2%🟢 Lam Research $LRCX +71.2%🟢 CrowdStrike $CRWD +62.9%🟢 Texas Instruments $TXN +58.9%🟢 Monolithic Power $MPWR +57.3%🟢 ASML $ASML +52.3%🟢 Cisco $CSCO +50.6%🟢 KLA Corp $KLAC +50.5%🟢 Ross Stores $ROST +39.4%🟢 CSX $CSX +39.0%🟢 Analog Devices $ADI +35.5%🟢 Old Dominion $ODFL +35.3%🟢 Diamondback Energy $FANG +35.0%🟢 Baker Hughes $BKR +32.8%🟢 DexCom $DXCM +25.7%🟢 Monster Beverage $MNST +25.7%🟢 Starbucks $SBUX +25.0%🟢 PACCAR $PCAR +21.2%🟢 Coca-Cola Europacific $CCEP +20.7%🟢 Marriott $MAR +20.2%🟢 Fastenal $FAST +18.9%🟢 Honeywell $HON +18.9%🟢 Amgen $AMGN +17.7%🟢 Amazon $AMZN +17.7%🟢 Microchip $MCHP +16.6%🟢 Mondelez $MDLZ +15.8%🟢 Google $GOOGL +13.8%🟢 Apple $AAPL +13.6%🟢 Broadcom $AVGO +12.5%🟢 Linde $LIN +12.2%🟢 Airbnb $ABNB +11.6%🟢 Keurig Dr Pepper $KDP +11.1%🟢 American Electric Power $AEP +10.9%🟢 Costco Wholesale $COST +10.4%🟢 Cintas CTAS +8.8%🟢 Cadence CDNS +8.8%🟢 Nvidia NVDA +7.6%🟢 Kraft Heinz KHC +6.6%🟢 Gilead Sciences GILD +6.1%🟢 Xcel Energy XEL +5.9%🟢 NXP Semiconductors NXPI +5.6%🟢 Vertex Pharmaceuticals VRTX +5.2%🟢 Exelon EXC +5.1%🟢 Paychex PAYX +4.2%🟢 ADP +3.6%🟢 Electronic Arts EA +2.7%🟢 Ferrovial FER +0.8%🟢 CoreWeave CRWV +0.2%🟢 Walmart WMT -0.2%🔴 Regeneron Pharmaceuticals REGN -1.2%🔴 PayPal PYPL -2.0%🔴 O'Reilly Automotive ORLY -2.0%🔴 PepsiCo PEP -2.8%🔴 Microsoft MSFT -3.9%🔴 Take-Two TTWO -5.1%🔴 MercadoLibre MELI -6.8%🔴 Rocket Lab RKLB -6.9%🔴 Axon AXON -7.1%🔴 Warner Bros. Discovery WBD -8.7%🔴 Booking BKNG -10.0%🔴 Roper ROP -11.9%🔴 DoorDash DASH -13.4%🔴 Qualcomm QCOM -13.7%🔴 Comcast CMCSA -14.4%🔴 T-Mobile TMUS -14.9%🔴 Meta Platforms META -15.7%🔴 GE HealthCare Technologies GEHC -17.1%🔴 Synopsys SNPS -17.2%🔴 IDEXX IDXX -17.4%🔴 Autodesk ADSK -20.9%🔴 PDD Holdings PDD -21.9%🔴 Netflix NFLX -23.5%🔴 Thomson Reuters TRI -24.5%🔴 Workday WDAY -25.4%🔴 Copart CPRT -25.6%🔴 Constellation Energy CEG -25.6%🔴 Shopify SHOP -27.2%🔴 SpaceX SPCX -27.8%🔴 Adobe ADBE -28.5%🔴 Honeywell Aerospace HONA -30.5%🔴 Palantir PLTR -30.8%🔴 Tesla TSLA -30.8%🔴 Intuitive Surgical ISRG -37.6%🔴 Strategy MSTR -38.6%🔴 AppLovin APP -41.3%🔴 Alnylam Pharmaceuticals ALNY -48.3%🔴 Intuit INTU -52.3%🔴

SPACE RACE: CHINA CLOSES THE GAP China is rapidly expanding its satellite capabilities, narrowing the technology gap with the U.S. Advanced surveillance, AI-powered imagery, the BeiDou navigation system, and new communications satellites are improving Beijing's ability to track military activity, support precision strikes, and strengthen its space network. U.S. officials warn these advances could challenge American military superiority and reshape the balance of power in space.

Space investing soared after SpaceX’s IPO captured the market’s imagination. But after the company wiped over $1 trillion from its peak market value, have investors already turned their backs on the stars? ProcureAM’s Andrew Chanin said SpaceX continues to hit key milestones